Immunotherapy for metastatic or recurrent head and neck cancer
The KEYNOTE-048 study examined the use of immunotherapy with pembrolizumab rather…
The KEYNOTE-048 study examined the use of immunotherapy with pembrolizumab rather than the standard treatment using cetuximab for head and neck cancer...